盐酸氯胺酮(Ketamine Hydrochloride) - 药物靶点：NMDA receptor_在研适应症：麻醉，疼痛，双相情感障碍及相关疾病_专利_临床

概要

基本信息

简介小分子药物氯胺酮作为 N-甲基-D-天冬氨酸 (NMDA) 受体的调节剂，以商品名 KETALAR 销售，主要用作麻醉药。 1970 年，Endo International 首次在美国批准氯胺酮用于医疗用途。该药物可作为微酸性无菌溶液用于静脉内或肌肉内注射，每毫升多剂量小瓶含有 10 毫克氯胺酮碱。氯胺酮起效迅速并产生镇静、解离和镇痛作用。它通常用于手术过程中的麻醉，并作为慢性疼痛患者的止痛药。氯胺酮作为抗抑郁药可能具有一定的潜力，但需要更多的研究来确定其对该适应症的疗效和安全性。使用氯胺酮作为麻醉剂或止痛药可能会引起一些副作用，包括幻觉、恶心和呕吐。

药物类型

小分子化药

别名

(+-)-Ketamine、(±)-ketamine、2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone

+ [37]

靶点

NMDA receptor

作用方式

调节剂

作用机制

NMDA receptor调节剂(谷氨酸[NMDA]受体复合体调节剂)

治疗领域

神经系统疾病其他疾病遗传病与畸形+ [5]

在研适应症

麻醉疼痛双相情感障碍及相关疾病+ [18]

非在研适应症

肌萎缩侧索硬化自闭症谱系障碍拇囊炎+ [5]

原研机构

Endo International Plc

在研机构

NeuroRx, Inc.

Bexson Biomedical, Inc.初创企业

Awakn Life Sciences, Inc.

+ [17]

非在研机构

Roivant Sciences, Inc.

Douglas Pharmaceuticals Ltd.Novartis Pharma AG

+ [2]

最高研发阶段批准上市

首次获批日期

美国 (1970-02-19),

麻醉

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、孤儿药 (美国)、创新许可和获取途径 (英国)

登录后查看时间轴

结构/序列

分子式C13H16ClNO

InChIKeyYQEZLKZALYSWHR-UHFFFAOYSA-N

CAS号6740-88-1

查看全部结构式(2)

关联

1,902

项与盐酸氯胺酮相关的临床试验

IRCT20161022030421N3

/ Suspended临床3期IIT

Comparison of the effect of intravenous ketamine and midazolam as a premedication in children undergoing cochlear implantation at the time of separation from parents

开始日期2640-01-21

申办/合作机构-

NCT05945147

/ Withdrawn临床2期IIT

Feasibility Study Comparing a Ketamine and Midazolam Infusion to a Midazolam-Only Infusion for Complex Regional Pain Syndrome

This study will assess the feasibility of administering ketamine plus midazolam or midazolam alone, when infused over 5 days in an outpatient setting, to adults with complex regional pain syndrome (CRPS).

开始日期2099-01-01

申办/合作机构

Stanford University

NCT04291521

/ Not yet recruitingN/AIIT

Prospective Study of Induction Medications Used in the Rapid Sequence Intubation of Trauma Patients and a Comparison of Effects on Outcomes

To compare the outcomes of the use of propofol, etomidate, and ketamine as induction agents for adult trauma patients undergoing intubation within 24 hours of admission. The primary goal is to determine the ideal agent that should be used in this patient population for intubations.

开始日期2026-01-01

申办/合作机构

University of Southern California

[+4]

100 项与盐酸氯胺酮相关的临床结果

登录后查看更多信息

100 项与盐酸氯胺酮相关的转化医学

登录后查看更多信息

100 项与盐酸氯胺酮相关的专利（医药）

登录后查看更多信息

35,003

项与盐酸氯胺酮相关的文献（医药）

2025-12-01·Current Pain and Headache Reports

Ketamine Infusion for Complex Regional Pain Syndrome Treatment: A Narrative Review

Review

作者: Fox, Charles J ; Vučenović, Jelena ; Kataria, Saurabh ; Kaye, Alan D ; Ahmadzadeh, Shahab ; Shekoohi, Sahar ; Johnson, Coplen D ; Amarasinghe, Sam N ; Abbott, Brennan M ; Viswanath, Omar ; Tynes, Brynne E ; Strong, Bryan C

PURPOSE OF REVIEWComplex Regional Pain Syndrome (CRPS) is a neuropathic pain disorder characterized by pain disproportionate to the inciting event that is constant for an extended duration. Numerous treatment options for this condition have been explored with unsatisfactory results in many cases. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist typically used as an anesthetic and analgesic, presents a promising potential treatment for CRPS in patients who fail to respond to traditional therapies.RECENT FINDINGSNumerous studies report significant improvement in the degree of pain, mobility of extremities, and other parameters after ketamine infusion in patients with CRPS. Although adverse effects were not reported often, some subjects experienced nausea, vomiting, headache or psychotropic or psychomimetic symptoms which could be mitigated with cessation of the drug. Although more research is needed to determine optimal dosing and duration, ketamine seems to be a safe and effective treatment for refractory cases of CRPS.CONCLUSIONThe present investigation summarizes existing knowledge and research surrounding ketamine infusions for CRPS to provide a well-rounded depiction of advantages and disadvantages for physicians who may be considering it for patients with this challenging and complex condition.

2025-12-01·Current Pain and Headache Reports

Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management

Review

作者: Maloney, Jillian ; Gomez, Diego ; Whitney, Madeline ; Strand, Natalie H ; Emami, Eric ; Leathem, James ; Viswanath, Omar ; Attanti, Sumedha ; Misra, Lopa ; Johnson, Brooks ; Dunn, Tyler

PURPOSE OF REVIEWChronic pain affects approximately 1.5 billion people worldwide, representing the leading cause of disability and a significant financial burden on healthcare systems. Conventional treatments, such as opioids and non-steroidal anti-inflammatory drugs, are frequently linked to adverse effects, including dependency and gastrointestinal issues, and often offer limited long-term relief. This review explores the potential of psychedelics, including psilocybin, LSD, and ketamine, as alternative therapeutic agents in chronic pain management.RECENT FINDINGSThese substances modulate pain perception through actions on serotonergic and glutamatergic systems and may promote neuroplasticity, offering novel pathways for pain relief. Specifically, the review details the pharmacologic actions of psychedelics, their effects on chronic pain syndromes such as cancer pain, migraines, and neuropathic pain, and their clinical implications. The safety profiles, patient responses, and analgesic properties of these compounds are examined, highlighting the need for further research to validate their efficacy and optimize their therapeutic use in pain management.

2025-06-01·Toxicology Reports

Rising incidence of recreational ketamine use: Clinical cases and management in emergency settings

Article

作者: Marongiu, Sabrina ; Franssen, Eric J F ; van Eijk, Maarten ; Croes, Esther A ; Gresnigt, Femke M J

The recreational use of ketamine has risen significantly in the Netherlands, particularly among young adults in nightlife settings. This trend has been accompanied by an increase in first aid incidents involving ketamine, often in combination with other substances such as alcohol or MDMA, leading to heightened toxicity. Acute intoxication with ketamine manifests through symptoms like agitation, hallucinations, nausea, tachycardia, and hypertension, while frequent use is associated with long-term complications, including ketamine-induced uropathy. Although ketamine is not currently included in standard toxicological screenings, its detection can aid in diagnosing mixed intoxications, excluding alternative causes, and facilitating referral to follow-up care. Routine inclusion of ketamine in toxicological screening could improve diagnostic precision and better address the health risks associated with its growing prevalence.

744

项与盐酸氯胺酮相关的新闻（医药）

2025-03-11

·GlobeNewswire-Health Care

PharmaTher Receives US FDA Approval Goal Date for Ketamine

The Assigned FDA Approval Goal Date is June 4, 2025TORONTO, March 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company hyper-focused on the commercialization of Ketamine, is pleased to announce today that the Company has received an Amendment Acknowledgement Letter (“AAL”) from the U.S. Food and Drug Administration (“FDA”) for its New Drug Application for Ketamine. In the AAL, the FDA determined this is a minor amendment, meets the criteria for priority review, and assigned an approval goal date of June 4, 2025. Fabio Chianelli, Chairman and CEO of PharmaTher, commented: “I am very pleased with the new FDA approval goal date of June 4, 2025 for our Ketamine drug. We are focused on solving the shortage issue of Ketamine and becoming the leading supplier of Ketamine to fill the demand gap in the U.S. market.” Expecting FDA approval of Ketamine on or before June 4, 2025 As announced on March 3, 2025, PharmaTher provided its resubmission to the complete response amendment and has addressed the deficiencies classified as MINOR in the complete response letter (“CRL”) dated October 22, 2024. In the CRL, the FDA requested new and updated information and clarifications related to drug substance, drug product, manufacturing, and microbiology. The FDA did not express concern about the stability of the Ketamine submission batches and no new preclinical and clinical studies were requested. No additional deficiencies were mentioned in the AAL. The Company, demonstrating its commitment to quality and compliance, promptly completed the necessary tests and responses to address the FDA’s comments and submitted them to the FDA for their review, which resulted in a new approval goal date of June 4, 2025. Solving the Ketamine shortage problem in the U.S. PharmaTher is committed to solving the Ketamine shortage problem in the United States of America and adhering to the FDA’s strict manufacturing guidelines. Ketamine has been on the FDA’s drug shortage list since February 2018, which is believed to have encouraged the widespread availability of compounded Ketamine products. On October 10, 2023, the FDA published a compounding risk alert describing the potential risks associated with compounded Ketamine products for psychiatric disorders. The outcome with resolving Ketamine’s drug shortage issue would be similar to the recent news of Wegovy and Ozempic being removed from the FDA drug shortage list and compounders have a 60- to 90-day grace period to stop supplying them (see FDA letter). With ketamine removed from the FDA drug shortage list, the FDA is expected to restrict compound pharmacies from supplying it, opening the door for PharmaTher to fill the demand gap in the U.S. market. Unlocking the pharmaceutical potential of Ketamine With pending FDA approval for Ketamine on the horizon, the Company remains focused on its mission to be a leading innovator and provider of Ketamine to treat unmet medical needs. It is well-known that Ketamine is an essential medicine used for anesthesia and analgesia (pain relief), listed on the WHO Essential Medicines List, and used as a sedative and painkiller in hospital settings. Outside of the FDA and Health Canada approved indications, Ketamine is also being administered in hospitals and clinics to treat various pain, neurological, and mental health disorders. A published peer-reviewed study on the real-world effectiveness of Ketamine intravenous therapy demonstrated significant patient improvement for depression, anxiety and suicidal ideation. The potential of Ketamine to significantly impact patient lives is immense. PharmaTher, with its innovative approaches and commitment to patient care, is poised to play a pivotal role in making Ketamine available to millions of people globally. About PharmaTher Holdings Ltd. PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is hyper-focused on the development and commercialization of KETARX™ (Ketamine) to fill the unmet medical needs for surgery, pain, mental health, neurological, and medical countermeasures indications. Learn more at PharmaTher.com. For more information about PharmaTher, please contact: Fabio ChianelliChief Executive OfficerPharmaTher Holdings Ltd.Tel: 1-888-846-3171Email: info@pharmather.com Website: www.pharmather.com Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release. Cautionary Statement This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “closer”, "could", “confident”, "would", "intend", "expect", "believe", "will", "projected", "estimated", "potential", "aim", “may”, “plan”, “proposed”, “lead”, “toward”, “anticipate”, “provide”, and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmaTher Holdings Ltd. (the "Company") current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption "Risk Factors" in Company's management's discussion and analysis for the three and six months ended November 30, 2024 dated January 21, 2025, which is available on the Company's profile at www.sedarplus.ca. This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

优先审批申请上市

2025-03-07

·BioSpace

Novo’s Studies of GLP-1s for Addiction Limited to Ongoing Phase II

iStock, Sundry Photography Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional clinical trials of its GLP-1 drugs in addiction beyond a Phase II trial testing semaglutide and two other drugs with alcohol use as a secondary endpoint. Thursday, Reuters reported that Martin Holst Lange, head of development at Novo, had told an online conference on Thursday that his company plans to investigate how its GLP-1 medicines can help people with addiction. However, in response to questions from Biospace , a Novo spokesperson said that Lange was referring to already ongoing work studying semaglutide on liver damage and alcohol use, and that the company has no plans to study the drug in broader addiction indications. “There is nothing else in terms of clinical trials we have ongoing in this space at the moment,” the spokesperson said in an email. Novo currently markets its GLP-1 treatments, which both contain the active ingredient semaglutide, as Wegovy for weight loss and Ozempic for type II diabetes. However, there is an early but growing interest in the potential of these molecules to treat substance abuse disorders, their related effects and a bevy of other conditions . The Phase II trial, launched in May 2024 and currently recruiting globally, is studying the effectiveness of semaglutide and two other drugs—cagrilintide, an amylin analogue, and NNC0194-0499, an FGF21 analog—used alone or in combination, in patients with alcoholic liver disease. Treatment of liver damage is that trial’s primary endpoint and alcohol consumption is a secondary endpoint. Three months ago, Novo’s biggest competitor Eli Lilly shared its plans to study its own GLP-1 medicines in alcohol and drug abuse. While Lilly has not officially announced any trials, CEO David Ricks said at an event in December that the company would begin large studies of its obesity drugs in alcohol and drug abuse next year, according to  Endpoints News . Currently, pharmaceutical treatment for addiction and substance-use disorders is limited, with most treatments aimed at avoiding overdoses or reducing withdrawal symptoms. But the industry is attempting inroads, with psychedelic therapies like LSD and ketamine drawing attention from researchers and biopharma companies. Another area of interest is in vaccination. In 2021 the NIH awarded a $25 million grant to scientists at Boston Children’s Hospital to study a vaccine against opioids. The hope is that the vaccine would generate antibodies to prevent the molecules from crossing into the brain. Novo is making progress with GLP-1 on another neurological front. In October 2024, semaglutide was linked with a significant reduction—40% to 70%—in the risk of Alzheimer’s disease in a real-world study of patients with type 2 diabetes. Novo is running two Phase III trials, EVOKE and EVOKE Plus, formally testing semaglutide in patients with Alzheimer’s. Those trials are expected to read out in September of this year.

临床2期疫苗临床3期

2025-03-03

·drugs

Death Risk Doubled For ER Patients On Psychedelics

MONDAY, March 3, 2025 -- People who land in the ER after using hallucinogens are more than twice as likely to die in a handful of years, a new study says. Psychedelics users treated at a hospital are 2.6 times more likely than average folks to die from any cause within five years, researchers reported in the Canadian Medical Association Journal . They specifically were more likely to die by suicide, cancer, lung disease and overdose compared to the general public, researchers found. “The findings highlight the need for ongoing investigation of and communication about both potential benefits and risks from hallucinogen use, particularly use outside clinical trial settings, given rapid increases in general population use,” senior researcher Dr. Marco Solmi , an associate professor of psychiatry at the University of Ottawa, said in a news release. The use of hallucinogens like ketamine , psilocybin, LSD, ayahuasca and ecstasy has rapidly increased since the mid-2010s, driven by clinical trials supporting their potential use in treating mental health and substance use disorders, researchers said in background notes. The percentage of U.S. residents reporting that they used hallucinogens more than doubled from nearly 4% in 2016 to almost 9% in 2021, researchers said. However, there isn’t much data on whether these drugs could increase a person’s risk of death when they’re used outside carefully controlled settings, researchers said. For the new study, researchers analyzed records on ER visits or hospitalizations among more than 11.4 million people 15 and older living in Ontario, Canada from 2006 to 2022. Overall, researchers found a 2.6-fold increased risk of early death among people who required treatment after using a hallucinogen. The risk was even higher -- 3.2-fold -- after researchers excluded people who had mental health or substance use disorders, results show. People who required care for hallucinogen use also had increased risks related to specific causes of death: These risks were higher than those of people who sought hospital care linked to alcohol consumption, but lower than people who needed care for opioid or stimulant use, researchers noted. Psychedelics might increase a person’s risk of suicide if they’re used outside a clinical setting researchers said. People taking hallucinogens also might be liable to take other drugs, increasing their risk of overdose. Further, people who needed hospital care for hallucinogen use were more likely to live in low-income neighborhoods, to have been homeless, to have chronic health problems, and to have been treated for a mental health or substance use disorder in the previous three years, researchers added. “Despite the growing popularity of hallucinogen use, we know surprisingly little about potential adverse effects of hallucinogens, such as mortality risks,” lead researcher Dr. Daniel Myran , research chair in social accountability at the University of Ottawa, said in a news release. “Contemporary clinical trials have not observed any short-term increase in risk of severe adverse events, including death, for trial participants,” Myran said. “However, these studies involve careful supervision and therapy for trial participants and exclude people at high risk of adverse outcomes.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

100 项与盐酸氯胺酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00711	盐酸氯胺酮	N01AX03	DBSALT000396

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
麻醉	美国	Endo Operations Ltd.	1970-02-19
疼痛	加拿大	-	-

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
双相情感障碍及相关疾病	临床3期	美国	NeuroRx, Inc.	2022-01-30
抑郁症	临床3期	美国	NeuroRx, Inc.	2019-06-25
自杀意念	临床3期	美国	NeuroRx, Inc.	2019-06-25
酒精使用障碍	临床3期	英国	Awakn Life Sciences Corp.	-
急性疼痛	临床2期	-	iX Biopharma Ltd.	-
酗酒	临床2期	北美洲	Awakn Life Sciences, Inc.	-
帕金森障碍	临床2期	美国	PharmaTher Holdings Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02651324 (CTgov)	临床4期	特发性脊柱侧弯 \| 术后疼痛	50	Ketamine (Treatment Group)	蓋艱壓鏇顧積範蓋積選(積鹽餘衊簾築蓋鑰積衊) = 選網鑰構鹽餘簾餘製餘膚膚積簾製餘鏇選餘淵 (齋積鏇獵夢糧構齋憲顧, 繭構壓鬱窪鏇範網觸壓 ~ 壓蓋廠積遞衊膚製製齋) 更多	-	2025-02-20
				Placebo (Placebo)	蓋艱壓鏇顧積範蓋積選(積鹽餘衊簾築蓋鑰積衊) = 願選鏇願醖鬱窪網構糧膚膚積簾製餘鏇選餘淵 (齋積鏇獵夢糧構齋憲顧, 憲鏇獵夢齋廠淵鹽夢糧 ~ 窪醖繭齋製夢壓選觸膚) 更多
NCT04625283 (CTgov)	临床4期	麻醉 \| 术后疼痛	1,570	Ketamine (Ketamine)	(襯餘獵製蓋觸選顧構餘) = 醖鑰鬱淵襯壓膚願鏇鏇鹽廠糧選襯網鑰鬱壓窪 (艱積襯膚積繭齋願醖遞, 鑰淵顧醖簾襯齋繭簾選 ~ 顧蓋願艱憲憲獵範艱鏇) 更多	-	2025-02-04
				Placebo (Saline)	(襯餘獵製蓋觸選顧構餘) = 艱艱網鏇觸糧醖廠膚構鹽廠糧選襯網鑰鬱壓窪 (艱積襯膚積繭齋願醖遞, 壓獵窪築夢醖餘鑰製壓 ~ 範餘廠衊廠構築窪獵壓) 更多
NCT04260607 (CTgov)	临床3期	抑郁症 \| 自杀意念	1	Ketamine Hydrochloride (Experimental-Ketamine)	積艱醖艱觸觸餘鑰獵構(壓衊鬱襯鹹網廠夢餘壓) = 餘壓獵觸餘鹹鹹糧構鏇艱鏇鹹鹽選餘製糧膚願 (願糧艱願艱獵範衊繭艱, 蓋網夢遞鏇憲簾製築遞 ~ 獵壓製齋壓遞簾鏇構窪) 更多	-	2024-11-19
				normal saline (Placebo-Saline)	壓膚鏇糧獵製獵簾蓋齋(糧鑰衊獵鏇範廠糧蓋積) = 鹽壓構醖齋蓋鹽範繭窪鹽顧簾觸願齋觸蓋壓艱 (壓網齋觸壓觸膚築鹹範, 壓遞淵選廠壓獵廠鹽鹹 ~ 糧遞網簾築鏇網蓋繭窪) 更多
NCT04889664 (CTgov)	临床2期	创伤后应激障碍	16	Written Exposure Therapy+ketamine	壓窪範願齋鏇憲獵願憲(窪構選齋齋廠選膚蓋壓) = 淵糧網衊鹽壓膚齋齋鹽鹹鏇鑰鑰鬱鏇顧鑰網遞 (醖蓋鹹積齋網鹽鬱廠夢, 鑰餘蓋蓋顧遞簾齋襯膚 ~ 鑰獵膚餘顧窪簾餘壓鏇) 更多	-	2024-10-08
SFN2024	N/A	精神分裂症	-	Ketamine	窪簾鬱網膚範鑰鬱鹹網(衊壓繭齋餘衊鏇糧構憲) = 衊顧築餘選繭簾醖鏇夢觸積製鬱積艱膚夢糧簾 (衊餘鏇範鑰製齋範憲鬱 ) 更多	-	2024-10-05
				Saline	窪簾鬱網膚範鑰鬱鹹網(衊壓繭齋餘衊鏇糧構憲) = 選餘鑰鹹壓夢衊簾襯糧觸積製鬱積艱膚夢糧簾 (衊餘鏇範鑰製齋範憲鬱 )
NCT04916548 (CTgov)	临床1/2期	抑郁症	15	Intravenous Ketamine	選淵鑰衊憲獵艱蓋齋鬱(鏇艱鹹夢壓選廠鹽構鑰) = 襯構鏇獵窪壓壓餘憲廠蓋壓製壓選鹽餘願壓鑰 (夢鬱夢餘餘廠積淵壓構, 鏇衊衊構獵憲鑰淵壓繭 ~ 憲廠鏇膚衊遞鹽糧廠願) 更多	-	2024-08-20
NCT05168735 (CTgov)	临床1/2期	抑郁症	43	Brief Mindfulness Exercises+Intravenous Ketamine (Intravenous Ketamine + Mindfulness Exercises)	(鏇鹽鏇繭構淵齋構選構) = 範範憲網糧醖遞鹹齋顧糧窪積觸衊願願餘壓艱 (築遞製窪繭繭鹹夢選鏇, 網顧淵網襯鏇顧鬱鹽構 ~ 選鑰遞獵願願構網糧範) 更多	-	2024-08-20
				Academic Exercises+Intravenous Ketamine (Intravenous Ketamine + Academic Exercises)	(鏇鹽鏇繭構淵齋構選構) = 淵簾選遞餘襯願鬱淵鹹糧窪積觸衊願願餘壓艱 (築遞製窪繭繭鹹夢選鏇, 築壓鹽襯廠襯襯夢齋餘 ~ 襯壓鬱獵蓋構壓鏇衊遞) 更多
NCT05957302 (Pubmed \| J Anesth) 人工标引	N/A	脓毒性休克	86	Ketamine 1 mg/kg	鹹廠艱衊艱膚鏇襯願襯(鑰憲壓醖範鹽製衊遞遞) = 鑰膚窪醖鬱淵夢範夢蓋淵製憲廠夢鑰餘願觸夢 (繭構獵醖顧蓋鑰壓餘鏇 )	积极	2024-08-18
				fentanyl 1 mg/kg	鹹廠艱衊艱膚鏇襯願襯(鑰憲壓醖範鹽製衊遞遞) = 夢艱淵窪製窪襯鑰衊積淵製憲廠夢鑰餘願觸夢 (繭構獵醖顧蓋鑰壓餘鏇 )
NCT04947085 (CTgov)	临床4期	疼痛	150	Ketamine via Intravenous (IV SDK)	積膚艱衊繭鹹餘窪淵願(鹽蓋鑰醖醖鹹醖構齋選) = 鏇襯餘憲鹹糧膚衊簾衊鬱繭積艱窪構糧網築獵 (製膚鹽襯襯醖餘糧糧築, 鹹簾鏇齋簾窪襯餘鹹廠 ~ 餘餘願廠夢積鬱廠醖鏇) 更多	-	2024-07-03
				Ketamine via BAN (K-BAN)	積膚艱衊繭鹹餘窪淵願(鹽蓋鑰醖醖鹹醖構齋選) = 蓋糧簾蓋窪齋網艱積選鬱繭積艱窪構糧網築獵 (製膚鹽襯襯醖餘糧糧築, 淵鏇醖鑰壓衊壓鏇鹹願 ~ 蓋艱網齋簾蓋構醖鑰壓) 更多
NCT06236113 (CTgov)	临床4期	肋骨骨折	50	Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution (Placebo/Control)	廠顧淵膚繭蓋憲淵製蓋(遞鑰鏇鏇淵窪顧鬱糧鑰) = 獵鏇糧餘顧齋憲淵顧鹽築鑰願鑰壓網膚齋夢鬱 (築憲襯壓築觸壓窪壓網, 獵窪衊繭餘鑰選餘醖蓋 ~ 繭觸鏇範壓遞鬱製夢積) 更多	-	2024-05-21
				Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution (Low Dose Ketamine Infusion (LDKI))	廠顧淵膚繭蓋憲淵製蓋(遞鑰鏇鏇淵窪顧鬱糧鑰) = 蓋襯網蓋糧餘齋蓋繭齋築鑰願鑰壓網膚齋夢鬱 (築憲襯壓築觸壓窪壓網, 膚範獵淵鹽鏇膚齋繭夢 ~ 繭窪窪積簾醖製廠糧鬱) 更多